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Structure and mechanism of a 
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Citrullination is a post-translational modification of higher organisms that deiminates arginines in 
proteins and peptides. It occurs in physiological processes but also pathologies such as multiple 
sclerosis, fibrosis, Alzheimer’s disease and rheumatoid arthritis (RA). The reaction is catalyzed by 
peptidylarginine deiminases (PADs), which are found in vertebrates but not in lower organisms. RA has 
been epidemiologically associated with periodontal disease, whose main infective agent is Porphyromonas 
gingivalis. Uniquely among microbes, P. gingivalis secretes a PAD, termed PPAD (Porphyromonas 
peptidylarginine deiminase), which is genetically unrelated to eukaryotic PADs. Here, we studied 
function of PPAD and its substrate-free, substrate-complex, and substrate-mimic-complex structures. 
It comprises a flat cylindrical catalytic domain with five-fold α/β-propeller architecture and a C-terminal 
immunoglobulin-like domain. The PPAD active site is a funnel located on one of the cylinder bases. It 
accommodates arginines from peptide substrates after major rearrangement of a “Michaelis loop” that 
closes the cleft. The guanidinium and carboxylate groups of substrates are tightly bound, which explains 
activity of PPAD against arginines at C-termini but not within peptides. Catalysis is based on a cysteine-
histidine-asparagine triad, which is shared with human PAD1-PAD4 and other guanidino-group modifying 
enzymes. We provide a working mechanism hypothesis based on 18 structure-derived point mutants.
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L-Citrulline (N5-carbamoyl-L-ornithine) is a non-proteinogenic amino acid that is an intermediate in the 
Krebs-Henseleit urea cycle in animals1. It is produced by the enterocytes of the small bowel in humans 
and its accumulation in plasma can cause citrullinemia, an autosomal recessive disorder characterized by 
increased citrulline secretion in the urine and neuropsychiatric symptoms2. Citrulline is also a biological 
precursor for nitric oxide and its therapeutic administration has been proposed for the mitochondrial 
MELAS syndrome3. Citrulline further results from free arginine by citrullination, which entails replace-
ment of the guanidino group with an ureido group through deimination. This removes the positive 
charge of the arginine side chain and liberates ammonia.
Of greater physiological relevance, however, is the citrullination of arginines in peptides and pro-
teins through post-translational modification4,5. Given the limited number of genes in the genomes of 
higher organisms, such post-translational modifications increase the structural and functional diversity 
of the proteomes4. Citrullination may result in changes in fold, function and half-life of proteins and 
peptides, and the reaction is catalyzed in a calcium-dependent manner by peptidylarginine deiminases 
(PADs). These occur only in vertebrates, where five close paralogs (PAD1-PAD4 and PAD6) have been 
described6–8. Their activity is essential for skin keratinization, neuron insulation, and plasticity of the 
central nervous system as well as histone core-protein regulation5,7. Furthermore, through involvement 
of PADs in apoptosis, autophagy, and NETosis, citrullination plays a major role in the immune system.
However, citrullination also has an established role in pathology, which has lately catapulted interest 
in the reaction since increased levels of citrullinated proteins are found in several if not all inflammatory 
diseases9 and have been directly implicated in Alzheimer’s disease, prion diseases, psoriasis, multiple 
sclerosis and tumorigenesis5. In a specific genetic background, citrullinated proteins act as autoantigens 
to generate anti-citrullinated protein antibodies, which participate in an abnormal autoimmune response, 
a hallmark of rheumatoid arthritis (RA10). The latter is a common systemic disease affecting ~1% of the 
general population in the developed world that is characterized by chronic inflammation of the synovial 
joints, eventually leading to progressive joint destruction and, despite many years of intensive research, 
its mechanisms of disease progression are still poorly understood. As to etiology, genetic factors, envi-
ronmental influences—such as smoking and oral contraceptives—, and concomitant microbial infections 
are risk factors for developing RA11.
Inflammation is also a hallmark of chronic periodontal disease (PD), which is among the most preva-
lent infectious diseases of mankind12. In its severe form, the disease affects the gums of 10–15% of adults, 
potentially leading to tissue destruction and tooth loss13. Its major causal agent is Porphyromonas gingi-
valis, a bacterium that is also implicated in cardiovascular diseases, respiratory diseases, diabetes, osteo-
porosis, and pre-term low birth-weight. More recently, epidemiological studies have further reported an 
increased prevalence of PD in RA14,15, which is consistent with the antique claim made by Hippocrates 
~2,400 years ago that removal of bad teeth cures arthritis16.
Within the virulence-factor armamentarium of P. gingivalis are several secreted cysteine peptidases 
such as lysine (Kgp) and arginine gingipains A and B (RgpA and RgpB). These are cysteine endopepti-
dases cleaving after lysines and arginines, respectively, and they participate not only in nutrient acqui-
sition but also in host-tissue destruction and defense inactivation17. Uniquely among microbes to date, 
P. gingivalis also produces a secreted PAD (called PPAD18), which protects P. gingivalis during acidic 
cleansing in the mouth through ammonia generated during host and endogenous protein citrullination19. 
PPAD does not require calcium for catalysis20 and is genetically unrelated with animal PADs and, like the 
latter and cysteine peptidases, its main catalytic residue is a cysteine (C351 in PPAD20).
Host PADs process arginines within polypeptide chains but not at their termini, i.e. they are effi-
cient endodeiminases but poor exodeiminases4. In contrast, PPAD citrullinates C-terminal arginines 
like those generated by the prior action of Rgps17, which may be facilitated by the surface co-localization 
of Rgps and PPAD20. In this way, PPAD complements endogenous PADs and creates new exogenous 
epitopes for autoimmune response, which have been associated with RA disease progression15. Taken 
together, all these results suggest that the link between RA and P. gingivalis-induced PD may result from 
PPAD-mediated citrullination15.
To shed light on the molecular aspects of this key enzyme for pathogenicity, we analyzed the structure 
and function of PPAD in various functional states and proposed a working model for the enzyme based 
on mutational studies, which places PPAD in a wider context with PADs and functionally more distant 
enzymes.
Results and Discussion
Molecular structure of PPAD. PPAD was recently reported to belong to a family of secreted P. gingi-
valis proteins, which includes Kgp and Rgps20. These proteins possess a ~75-residue C-terminal domain 
(CTD) for maturation and translocation through the outer membrane via the PorSS, PerioGate or Type-IX 
secretion system, which removes the CTD upon secretion21. Accordingly and similarly to Kgp and Rgps, 
full-length PPAD would span a pro-peptide, a catalytic domain (CD), an immunoglobulin-superfamily 
domain (IgSF), and a CTD18. We obtained a fragment of PPAD by homologous overexpression in P. 
gingivalis that was equivalent to the purified form from P. gingivalis supernatant18 and, thus, lacked the 
pro-peptide and the CTD (residues A44-A475 ; see Table 1). We solved three distinct structures to high 
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resolution from different protein preparations, which crystallized in different space groups: substrate-free 
(to 1.5 Å resolution), a substrate-mimic (1.4 Å), and a substrate complex (1.8 Å; see Table 2).
The PPAD two-domain moiety (CD plus IgSF; Fig. 1) shows approximate maximal dimensions of 55 Å
(height) × 57 Å(width) × 50 Å(depth) according to the orientation of Fig. 1a and lacks any bound calcium 
ion, thus explaining why it is not needed for activity. Overall, it resembles a tooth—with the 316-residue 
CD featuring the crown and IgSF the root—, which is reminiscent of the gross overall shape of Kgp and 
RgpB despite completely different functions and CD architectures (see Fig. 2b in22 and Fig. 2a in23). The 
neck is the interface between the two domains, and the active site is at the cusp, on the grinding sur-
face (see below). The CD (A44-K359; see Fig. 1a–c) comprises eight helices and 20 β -strands and is a flat 
cylinder made up by a distorted five-fold α /β -propeller arranged around a central shaft. The PPAD CD 
cylinder has an upper entry base, which coincides with the tooth cusp, and an opposite lower exit base 
at the neck (Fig. 1a). Around the shaft, five propeller blades (I to V) spanning between 47 (blade III) and 
76 (blade I) residues are sequentially arranged counterclockwise according to Fig. 1b,c. Each blade starts 
on the entry base with a loop connected to the previous blade and consists at least of a three-stranded 
twisted β -sheet with an inner, a middle and an outer strand, plus one helix. The inner strand runs across 
the cylinder to the exit base paralleling the central shaft. A short loop links the inner strand with the 
antiparallel middle strand, which runs in the opposite direction towards the entry base. This strand is 
connected through another loop with the helix, which lines the cylinder side wall. Finally, the helix is 
linked to the outer strand, which parallels the middle strand and likewise lines the cylinder side wall. Into 
this minimal architecture—found only in blade V (Fig. 1c)—, additional structural elements are inserted 
in each blade, thus accounting for overall blade asymmetry and chain lengths. In particular, a sodium ion 
is pinched by the inner strand and the consensus helix of blade II and is bound in an octahedral manner 
by six oxygens at distances of 2.30–2.63 Å: D148O, D158O, and two solvent molecules coplanar with the 
cation; and apically by D147Oδ 1 and D158Oδ 1.
Preceding the first blade, an N-terminal extension (A44-R63) is found attached to blade II on the cyl-
inder side wall running from the entry base to the exit base (Fig. 1a–c). Here, the polypeptide undergoes 
Name Sequence (5′−>3′) Name Sequence (5′−>3′)
pTCowPPADf tgcagctagctccttaaggtggatggatatacg H236Fs ggcaagtatttggcaccgaa
pTCowPPADr ctgacgcatgccaatcggtcgttagagttctcc H236Rs gatatattcgccgttcggatct
W127AFt tcttacgctacacgcgactataccggttggttcgcaa H236AFt aacgctgtggactgttggggcaagtatttggcaccgaa
W127ARt gtcgcgtgtagcgtaagagtcagttttcgcaatgatgaa H236ARt ccaacagtccacagcgttgatatattcgccgttcggatct
D130Fs tataccggttggttcgcaa H236NFt aacaatgtggactgttggggcaagtatttggcaccgaa
D130Rs gtcagttttcgcaatgatgaa H236NRt ccaacagtccacattgttgatatattcgccgttcggatct
D130AFt tcttactggacacgcgcttataccggttggttcgcaa D238AFt aaccatgtggcttgttggggcaagtatttggcaccgaa
D130ARt agcgcgtgtccagtaagagtcagttttcgcaatgatgaa D238ARt ccaacaagccacatggttgatatattcgccgttcggatct
D130NFt tcttactggacacgcaactataccggttggttcgcaa D238NFt aaccatgtgaattgttggggcaagtatttggcaccgaa
D130NRt gttgcgtgtccagtaagagtcagttttcgcaatgatgaa D238NRt ccaacaattcacatggttgatatattcgccgttcggatct
R152AFs cctcgtcctaacgatgatga D239AFt aaccatgtggacgcttggggcaagtatttggcaccgaa
R152ARs cacgagacctactttgttcgtatc D239ARt ccaagcgtccacatggttgatatattcgccgttcggatct
R152AFt gactttatttataacgcccctcgtcctaacgatgatga D239Eft aaccatgtggacgaatggggcaagtatttggcaccgaa
R152ARt ggcgttataaataaagtccacgagacctactttgttcgtatc D239ERt ccattcgtccacatggttgatatattcgccgttcggatct
R154Fs gaattccccaaatacgaagc D239SFt aaccatgtggactcttggggcaagtatttggcaccgaa
R154Rs gcggttataaataaagtccacg D239SRt ccaagagtccacatggttgatatattcgccgttcggatct
R154AFt cctgctcctaacgatgatgaattccccaaatacgaagc N297AFs acaacagggtatttgttcctg
R154ARt atcatcgttaggagcagggcggttataaataaagtccacg N297ARs tgtacggttgttcattggtg
R154EFt cctgaacctaacgatgatgaattccccaaatacgaagc N297AFt cggcttctctgattctgaacaacagggtatttgttcctg
R154ERt atcatcgttaggttcagggcggttataaataaagtccacg N297ARt tcagaatcagagaagccgtgtacggttgttcattggtg
T180Fs acatgacggacggatatgga C351Fs ggtagcggataagggctatctc
T180Rs tgagcttcatcccgaacatc C351Rs agggcatctgttcctaaccaag
T180AFt agcaggctggtggcaactacatgacggacggatatgga C351AFt gcatgctcgtactcacgaggtagcggataagggctatctc
T180ARt agttgccaccagcctgcttgagcttcatcccgaacatc C351ARt tcgtgagtacgagcatgcagggcatctgttcctaaccaag
G182Aft agcagaccggtgctaactacatgacggacggatatgga C351SFt gcattctcgtactcacgaggtagcggataagggctatctc
G182ARt agttagcaccggtctgcttgagcttcatcccgaacatc C351SRt tcgtgagtacgagaatgcagggcatctgttcctaaccaag
Table 1.  Primers used for PPAD single-point mutagenesis. Restriction enzyme recognition sequences are 
underlined.
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a kink and, paralleling the inner strand of blade II, runs along the exit base between blades II and III 
until the central shaft. There, it runs upward as the middle strand of blade I. The C-terminal segment 
after blade V enters blade I and provides an extra helix followed by the inner strand of the consensus 
topology, thus internally fastening the molecule like a Velcro strip. Thereafter, the polypeptide reaches 
the exit base of the CD and enters the C-terminal 106-residue IgSF domain.
The IgSF domain (G360-E465) is a distorted 4 + 5-stranded β -sandwich (strands β 21-β 29) with an 
antiparallel back sheet (β 21↓ -β 23↑ -β 26↓ -β 25↑ ) and a mixed front sheet (β 22↓ -β 28 + β 29↓ -β 27↑ -β 24↓ -
β 25↑ ) whose planes are rotated away by ~25°. The right lateral flank of the domain is closed by strand 
β 25, whose N-terminal and C-terminal halves participate, respectively, in the front and back sheets. The 
left lateral flank is much wider and open, and contains a bulge dividing the second strand from the left of 
the front sheet in two (β 28 and β 29). This bulge interacts with the exit base of the CD (Fig. 1a). Overall, 
the topology and strand-connectivity of PPAD IgSF is strongly reminiscent of that of Kgp and RgpB22–24, 
but while the width (~25 Å) and depth (~20 Å) of the domains are similar, the length—along the strands 
of the sheets—is much greater in PPAD than in gingipains (~50 Å vs. ~35 Å).
Active site of PPAD. The propeller shaft in PPAD is rather solid, with a shallow cavity on its entry 
base coinciding with the tooth cusp that contains the active site (Fig. 1a,b). The latter is mainly a narrow 
funnel-like hole, which accommodates an arginine side chain of a peptidic or protein substrate. It is 





Space group P212121 C2 P212121
Cell constants (a, b, c, in Å; 
β in °) 58.56, 60.30, 113.68, 90.00 105.36, 59.32, 84.61, 126.60 60.53, 71.31, 105.66, 90.00
Wavelength (Å) 0.9786 0.9795 0.9795
No. of measurements/unique 
reflections 288,438/64,233 254,674/38,882 1,133,182/90,283
Resolution range (Å) 
(outermost shell)a 42.0–1.50 (1.59 − 1.50) 67.9 − 1.80 (1.90 − 1.80) 46.1 − 1.40 (1.48 − 1.40)
Completeness (%) 98.5 (95.7) 99.3 (98.9) 99.6 (97.5)
Rmergeb 0.041 (0.190) 0.062 (0.529) 0.042 (0.305)
Rr.i.m. [= Rmeas]c/ CC(1/2)c 0.047 (0.217)/0.998 (0.973) 0.067 (0.584)/0.999 (0.927) 0.043 (0.321)/1.000 (0.973)
Average intensityd 21.0 (7.4) 22.5 (3.7) 36.3 (8.5)
B-Factor (Wilson) (Å2)/Aver. 
multiplicity 25.0/4.5 (4.1) 29.2/6.5 (5.6) 19.3/12.6 (10.1)
Resolution range used for 
refinement (Å) 42.0 − 1.50 48.6 − 1.80 46.2 − 1.40
No. of reflections used (test 
set) 64,233 (772) 38,882 (699) 90,283 (903)
Crystallographic Rfactor (free 
Rfactor)b
0.157 (0.177) 0.156 (0.182) 0.146 (0.149)
No. of protein atoms/solvent 
molecules/neutral (covalent) 
ligands/ionic ligands
3,321/460/7 glycerol, 3 p-
thiopyridine, 1 S-oxo/1 Na+
3,296/426/5 glycerol, 1 Cys, 1 
Met-Arg dipept./1 Na+, 2 N3−, 
1 Cl−
3,300/689/3 glycerol, 1 imidazole, 
1 Asp-Gln dipept./1 Na+, 1 N3−, 1 
Cl−, 5 PO43−
Rmsd from target valuese
 bonds (Å)/angles (°) 0.010/1.03 0.010/0.99 0.010/1.05
 Average B-factors (Å2) 24.4 28.6 17.4
All-atom contacts and geometry analysisf
 Residues
  in favored regions/
outliers/all residues 409 (97.6%)/0/419 401 (97.1%)/0/413 411 (97.9%)/0/420
  with poor rotamers/bad 
bonds/bad angles 2 (0.56%)/0/0 3 (0.85%)/0/1 (0.24%) 2 (0.56%)/0/0
  with Cβ deviations 
> 0.25 Å/ clashscore 0/3.62 (96
th percentile) 1/3.34 (98th percentile) 0/3.47 (96th percentile)
  MolProbity score 1.23 (97th percentile) 1.29 (98th percentile) 1.17 (97th percentile)
Table 2.  Crystallographic data. aData processing values in parenthesis refer to the outermost resolution 
shell. bFor definitions, see Table 1 in55. cFor definitions, see56,57. dAccording to the XDS program40. Average 
intensity is < I/σ (I)> of unique reflections after merging. eAccording to Engh and Huber58. fAccording to 
MOLPROBITY53,59.
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framed by the main chain and side chains of the loops connecting blades I and II, II and III, III and IV, 
and V and I; segment β 7-loop β 7α 3-α 3 of blade II; and helix α 8 of blade I (Figs 1b and 2a–c). In the 
substrate-free structure, which was obtained with DTDP-treated wild-type (wt) protein, catalytic C351, 
nearby C239 and distal C462 residues are covalently modified by what was conservatively interpreted as 
Figure 1. Overall structure and topology of PPAD. (A) Ribbon-type plot of PPAD in a lateral view 
revealing its tooth-like shape, which consists of regions assignable to cusp, crown, neck and root. The upper 
N-terminal cylindrical catalytic domain (CD; residues 44–359; top entry base and bottom exit base) is 
shown with the N-terminal segment in yellow and each of its constituting blades (I to V) in one color (blue, 
magenta, orange, red, and green). The C-terminal IgSF-like domain (residues 360–465) is shown in grey 
for its β -strands (labeled β 22-β 29) and white for loops and coils. A sodium ion is shown as a blue sphere 
and a black arrow pinpoints the Michaelis-loop. (B) Top view onto the entry base of the CD cylinder after 
a horizontal 90°-rotation of (A). The helices (α 1-α 8) and strands (β 1-β 20) of the CD are labeled. Catalytic-
triad-residue (C351, H236 and N297) side chains are shown and labeled in red to highlight the active site in 
the center of the α /β -propeller. A black arrow pinpoints the Michaelis-loop. (C) Topology scheme of the 
five-bladed PPAD CD with strands as arrows and helices as cylinders with their respective limiting residues; 
coloring as in panels (A) and (B). The three catalytic residues of (B) are shown as pink asterisks, and the 
Michaelis-loop is denoted by a black arrow.
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Figure 2. Active-site architecture. (A) Stereo image of substrate-free PPAD CD, which actually corresponds 
to a thiopyridine modified state, with the Michaelis-loop (V226-V237) shown in red. Selected side chains 
are displayed with their carbons in light blue and labeled. (B) Same view as in (A) of the substrate-mimic 
complex, with the Michaelis-loop in green, unmodified cysteines, side-chain carbons in tan and relevant 
solvent molecules to illustrate the NH3-exit/H2O-entry and hydroxide channels as spheres in light blue (see 
also Fig. 4a). The bound aspartate-glutamine dipeptide is further shown with its carbons in turquoise. ① 
labels D130 and ② labels D238. (C) Same view as in (A) and (B) of the substrate complex, with the Michaelis-
loop in green, unmodified cysteine C239 (C351 is replaced by alanine), and side-chain carbons in pink. The 
bound methionine-arginine dipeptide is further depicted with its carbons in purple. ① labels D130 and ② 
labels D238.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:11969 | DOi: 10.1038/srep11969
a 4-thiopyridyl moiety. The C239 side chain is even found in two alternate conformations, one bound 
to thiopyridine and the other with the sulfur as sulfoxide (Fig.  2a). This indicates overall flexibility of 
active site residues in PPAD due to the absence of a bound substrate and suggests that the covalent 
modifications of the Sγ atoms do not distort the general unbound conformation of PPAD. In addition, 
segment V226-V237 of the loop connecting blades III and IV, hereafter the “Michaelis loop”, is in an open 
conformation, thus consistent with a structure that can bind a substrate. In particular, Y233 at the most 
exposed part of the loop points to bulk solvent (Fig. 2a). We further obtained a substrate-mimic com-
plex of DTDP-untreated wt PPAD with dipeptide aspartate-glutamine, and a true substrate complex of 
DTDP-untreated PPAD–C351A with dipeptide methionine-arginine. The identification of the peptides 
was based on high-resolution Fourier maps and surrounding binding partners. The complexes were 
obtained serendipitously, and all attempts to obtain complexes with other substrates or products failed. 
We hypothesize that DTDP-treatment precludes substrate binding and, thus, protects the unbound con-
formation, while lack of such treatment causes the enzyme to trap substrates or mimics during bio-
synthesis or purification. The complex structures are equivalent, including the backbone of the bound 
dipeptides (Fig. 2b,c), except for some minimal displacement and the differing side chains (Fig. 2b,c), so 
the substrate complex is taken hereafter as reference except for issues dealing with C351Sγ , for which the 
substrate-mimic complex will be referred to.
The complex structures allowed us to identify PPAD elements required for substrate binding and 
catalysis. Comparison with the substrate-free structure revealed overall coincidence of the complexes 
except for the rearrangement of the Michaelis loop (maximal displacement 7.5 Å at N230Cα ), which 
adopts a closed conformation that traps the substrate arginine side chain (Fig. 2b). This causes H196 to 
be rotated ~100° around its χ 1 angle toward bulk solvent and Y233 to be displaced by 4.1 Å and slightly 
reoriented for its side chain to bind the substrate (see below). Michaelis-loop rearrangement further 
causes ~90° rotation of H236 around its χ 2 angle, so that its Nδ 1 atom is apical to the guanidinium plane 
(3.2 Å away from arginine Cζ atom; see below) and may play a role in catalysis (see below). Catalytic 
C351Sγ , at the bottom of the cleft, occupies the opposite apical position and the atom is further in bind-
ing distance from N297Oδ 1 (3.3 Å), which could potentially assist in catalysis (see below). N297Nδ 2, in 
turn, is in binding distance of D238Oδ 1 (3.3 Å). The guanidinium group is further tightly bound by D238 
through a double salt bridge with arginine Nη 1 and Nη 2 atoms (2.9 Å and 3.0 Å), by the main-chain 
carbonyl of T346 (3.2 Å away from atom Nη 1), and by D130 through a second double salt bridge with 
arginine Nε and Nη 2 atoms (2.8 Å and 2.9 Å). D130 becomes rotated around its χ 1 angle by ~60° upon 
substrate binding, thereby exchanging its tight hydrogen bond with T180Oγ 1 (2.6 Å) in the substrate-free 
structure with binding of the substrate guanidinium group. These five interactions of the guanidinium 
group occur roughly in the plane of the latter. The aliphatic part of the arginine is bound between the 
hydrophobic side chains of I234 and W127 (both 3.7 Å apart). The latter is held in place by a hydrogen 
bond between its Nε 1 atom and D347Oδ 1 (2.9 Å), which also confers to the tryptophan a potential role 
in overall structure maintenance due to its stabilizing function of the loop connecting blades V and I 
(see below). Interestingly, two small solvent-accessible channels are found roughly on either side of the 
guanidinium plane, on the right and the left in Fig. 2b. The left channel, hereafter “NH3-exit/H2O-entry 
channel,” is framed by segments T290-N297, N230-E232, G345-T346, R252, H258, and, in particular, C239, which 
is closest to the substrate guanidinium and thus acts as a gatekeeper of the channel. The right channel, 
in turn, is shallower and does not reach the substrate but rather H236Nε 2, which is bound to two solvent 
molecules (see below). This “hydroxide-entry channel” is framed by Y233-N235, N151-R152, I197, and E201.
On the outer border of the active-site cavity, the main chain of the substrate is tightly bound through 
six interactions. The C-terminal carboxylate is linked by a double salt bridge with R152Nη 2 (3.0 Å) and 
Nε (2.8 Å). In addition, one of the carboxylate oxygens is further bound by R154Nη 1 (2.9 Å) and the 
other by Y233Oη (2.8 Å). The latter atom also binds the main-chain amido nitrogen (3.4 Å), and the 
preceding peptide carbonyl is hydrogen-bonded by R154Nη 2 (2.7 Å). This interaction seems to be the 
main factor responsible for the selectivity of PPAD for peptidylarginines over free arginine18. In addition, 
these interactions draw an intricate network to fix the substrate in the cleft, which makes it difficult to 
imagine how a substrate with C-terminal extension to the arginine, i.e. an endodeiminase substrate, 
would be bound by PPAD, as a C-terminally extended peptide would collide with Y233 and R152 side 
chains (Fig. 2b,c). Finally, lack of specific interactions with atoms upstream of the last peptide bond of 
the substrate accounts for PPAD’s capacity to non-specifically turn over both peptides and proteins with 
C-terminal arginines, i.e. as long as the C-terminus is freely accessible.
Peptidylarginine deiminase activity and mutant studies in vitro. PPAD is an efficient deimi-
nase of peptides including bradykinin and benzoylglycylarginine18, EGF and anaphylatoxin C5a20, and 
Rgp-derived fibrinogen peptides, as well as a large set of bacterial cell-envelope proteins truncated by 
Rgps. To provide additional data on the endo- and exodeiminase activities of PPAD in vitro, we tested 
two octapeptides of equivalent charge derived from the physiologically-relevant bradykinin precursor 
sequence, respectively with an arginine at position six (G-F-S-P-F-R-S-S; Fig. 3a) and at the C-terminus 
(P-P-G-F-S-P-F-R; Fig. 3b). We found that peptidylarginine exodeiminase activity of PPAD was nearly 
5,500 times higher than endodeiminase activity. This supports the structural findings above. In addition, 
detailed inspection of the final refined Fourier maps and thermal displacement parameters of atoms Nη 1, 
Cζ , and Nη 2 of all twelve internal arginines of the substrate-mimic complex of PPAD, which was refined 
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Figure 3. PPAD activity assays. (A) Endo- and (B) exo-deimininase activity assays in vitro of P. gingivalis 
W83 wt PPAD against peptides of sequence G-F-S-P-F-R-S-S and P-P-G-F-S-P-F-R, respectively. Peptides 
are shown before (blue HPLC chromatograms) and after reaction with PPAD (red HPLC chromatograms). 
Citrullination caused a shift in the retention time of the peptides when compared with the original ones 
and was confirmed by mass spectrometry. Based on peak integration, the velocity of reaction was calculated 
for both peptides, which indicated that peptidylarginine exodeiminase activity of PPAD was nearly 5,500 
times higher than endodeiminase activity based on reaction velocity (32,700 vs. 6 pmol·mU−1·h−1). (C) 
Stereo image depicting the 11 positions subjected to point mutagenesis and activity measurements (see (C) 
and (D)). The Michaelis-loop is shown in green for reference. (D) PPAD expression monitoring through 
Western-blot analysis of whole bacterial cultures resolved on SDS-PAGE and probed with an anti-PPAD 
antibody. The samples correspond to those of the abscissa of panel (E). (E) Relative deiminase activity in 
front of N-acetylarginine of wt W83 strain supernatant (W83), of a PPAD-deletion mutant strain (Δppad), 
of the latter containing plasmid pTPP for wt PPAD overexpression (pTPP; reference 100%), and a cohort of 
single point mutants around the active site encoded by pTPP variants.
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with data to very high resolution (1.4 Å; see Table 2), revealed no significant evidence for citrullination, 
strongly suggesting that PPAD produced by homologous overexpression in P. gingivalis is not endocit-
rullinated. Taken together, all these findings strongly support that PPAD is an exodeiminase, as already 
suggested in the initial report in 199918, and that N-terminal arginines of peptides, endosubstrates and 
standalone arginines are only modified at a much lower rate, if at all18.
In order to discern the functional role of the distinct residues identified in the structures above, we 
constructed a cohort of 18 single-point mutants of positions 127, 130, 152, 154, 180, 182, 236, 238, 239, 
297 and 351 (Table  1 and Fig.  3c) and assessed the deiminase activity of the respective cell cultures 
relative to the wt. Difficulties in the production of wt and mutant PPADs, which were obtained from P. 
gingivalis cultures, precluded more extensive enzymatic analyses with purified protein. Mutant expression 
levels were equivalent to those of the wt as monitored by Western-blot analysis, thus pointing to properly 
folded proteins. The sole exception was W127A, which in accordance with a structural role in addition 
to a substrate-binding role (see above), was not produced in detectable amounts (Fig. 3d). As expected, 
activity was completely abolished when mutating catalytic C351—to either alanine or serine—, but also 
when replacing D238 or H236—to either alanine or asparagine—, which participate in substrate guanidin-
ium Cζ atom pinching (Fig. 3e). N297, in binding distance of C351Sγ , likewise yielded an inactive enzyme 
when replaced with alanine. D130, which strongly binds the guanidinium, is also indispensable, and C239, 
the gatekeeper of one of the two solvent channels, is also relevant as its alanine and serine mutants 
were just ~8% active and its glutamate mutant was completely inactive. G182, in turn, is required to be 
side-chain depleted as it shuts the bottom of the pocket and is close to H236 and D130. Its replacement 
with alanine yielded a complete loss of activity. In contrast, T180, which interacts with the two latter resi-
dues, is unessential and its alanine mutant still had ~66% activity. Interestingly, R152, which establishes a 
double salt bridge with the substrate carboxylate, is absolutely indispensable for activity, while the second 
carboxylate-binding arginine, R154, is less relevant, with its alanine mutant still showing ~30% activity. 
Its glutamate mutant, however, which introduces a negative charge next to the also negatively-charged 
substrate carboxylate, thus causing repulsion, was less than ~10% active.
Mechanism of peptide citrullination by PPAD. We propose the following chemical mechanism of 
function of PPAD, which includes a catalytic triad (C351-H236-N297) and seven steps proceeding over two 
tetrahedral and one planar-thiouronium covalent reaction intermediates (Fig. 4a,b).
In the substrate-free state, the Michaelis-loop containing Y233 is in an open conformation, which ena-
bles peptides with a C-terminal arginine to be accommodated at the active site. The arginine becomes 
firmly anchored through electrostatic interactions of the guanidinium group with the side chains of 
D238 and D130, being positioned in an extended conformation and appropriately oriented for catalysis. In 
addition, R152 and R154 bind the C-terminal carboxylate of the arginine and the carbonyl of the preceding 
peptide bond. Moreover, formation of this Michaelis complex (Fig.  4b, I) entails major rearrangement 
of the Michaelis loop, which occludes the active site and causes Y233 to further bind the C-terminal 
carboxylate of the substrate. Rearrangement further entails that the side chain of H236 is rotated, as a 
result of which the plane of the guanidinium group becomes pinched between H236Nδ 1 and C351Sγ , and 
H236Nε 2 is solvent-bound in the hydroxide-entry channel (Fig.  4a,b). This geometry was determinant 
for the identification of H236 as the general base/acid of the mechanism and of the guanidinium Nη 1 
atom as the nitrogen atom of the leaving ammonia product. In addition, C351Sγ is hydrogen-bonded to 
N297Oδ 1, which probably enhances the nucleophilicity of the catalytic sulfur. In the first step of the reac-
tion, C351Sγ performs a nucleophilic attack on the sp2-like planar Cζ atom of the substrate guanidinium 
(Fig. 4b, I), giving rise to the first neutral tetrahedral reaction intermediate and yielding an sp3-like Cζ 
atom. Concomitantly, H236, which acts first as a general base, abstracts a proton from Nη 1, and the latter 
captures the proton from the catalytic thiol group. The histidine is now in a diprotonated state (Fig. 4b, 
II). The tetrahedral intermediate collapses to a positively-charged planar thiouronium covalent inter-
mediate and ammonia, which receives a proton from H236Nδ 1, now acting as a general acid (Fig. 4b, II 
and III). Ammonia leaves the active site through the NH3-exit/H2O-entry channel (Fig. 4a) and reaches 
the surface of the enzyme. In the next step, a solvent molecule—probably a water—occupies the former 
position of ammonia and becomes polarized by the side chain of D238 and H236Nδ 1. The latter again acts 
as a base and abstracts a proton from the water molecule, which performs a nucleophilic attack on the 
central carbon of the thiouronium (Fig. 4b, IV). This yields the second neutral intermediate centered on 
sp3-like tetrahedral Cζ and diprotonated H236 (Fig. 4b, V). The intermediate itself collapses to a citrul-
linated product and the intact catalytic cysteine mercapto group, which becomes hydrogen-bonded to 
N297Oδ 1. The repulsion between D238 and the carbonyl oxygen of the neutral reaction product may pro-
vide the driving force for clearance of the latter from the active-site cleft (Fig. 4b, VI). Finally, a hydroxide 
resulting from the reaction of ammonia with water may enter the active site through the hydroxide-entry 
channel and replace one of the two solvent molecules bound to H236Nε 1. The latter histidine transfers 
a proton to the hydroxide and a proton shift from Nδ 1 to Nε 2 restores the functional monoprotonated 
state of H236, thus leaving the active site posed for a new round of reaction (Fig. 4b, VII).
Structural similarity of PPAD catalytic domain. PPAD CD conforms to the structural require-
ments of the guanidino-group modifying enzyme superfamily (GME; see Fig.  5a–c), which adopts 
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Figure 4. Proposed peptide citrullinating mechanism of PPAD. (A) Composite picture in stereo of the 
active site of PPAD (see also Fig. 2) based on the substrate-mimic complex ribbon plot colored as in Fig. 2b. 
Only elements engaged in substrate binding and catalysis are depicted. Residue side chains taken from the 
substrate-mimic complex are shown with carbons in light blue (C351), those from the substrate complex in 
white (Y233, H236, D238, N297, R152, R154, and W217), and those from the unbound structure in pink (Y233 and 
H236). The Michaelis loop is shown in the open conformation of the unbound structure in pink and in the 
occluded conformation of the substrate(-mimic) complexes in red, a purple straight arrow highlights the 
rearrangement upon substrate binding. The substrate arginine depicted belongs to the substrate complex 
(carbons in turquoise). Solvent molecules from the substrate-mimic complex in light blue highlight the 
NH3-exit/H2O-entry channel on the left and those in purple the hydroxide-entry channel on the right. The 
rotation of the H236 side chain from the substrate-unbound to the bound conformation is pinpointed by a 
curved purple arrow. (B) Proposed biochemical mechanism of action of an enzymatic activity cycle in seven 
steps (I to VII). The substrate arginine and product citrulline are shown with bonds in bold, hydrogen bonds 
are shown as dashed lines.
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similar five-fold α /β -propeller folds and catalyzes chemical processing of (methylated) guanidine groups 
as found in the citrullinating GME members: PADs, PPAD, agmatine deiminases (AgDIs), and arginine 
deiminases (ADIs), which are all dimers or tetramers with the exception of PPAD25. AgDIs deiminate 
isolated agmatine (1-[4-aminobutyl]-guanidine) to N-carbamoylputrescine and ammonia as part of 
mechanisms by which energy is harnessed for growth26, and they are missing in higher eukaryotes25. 
ADIs, in turn, citrullinate standalone arginine and protect cells from acidic environments. They are 
found in plants and microorganisms but are likewise absent from animals27. Both families do not have 
extra domains further to the catalytic α /β -propeller.
To date, only the structures of human PAD2 and PAD4 have been determined among PADs8,28, and 
they comprise a ~375-residue calcium-dependent α /β -propeller domain preceded by two IgG domains 
(see Fig. 1 in8 and28), which are unrelated to PPAD IgSF further to being all-β protein domains. Among 
AgDIs, structures have been reported from Enterococcus faecalis (Ef; Protein Data Bank (PDB) access 
code 2JER26) and Helicobacter pylori (Hp; PDB 3HVM29), and other potential relatives have been depos-
ited with the PDB but not functionally analyzed or published (PDB 2EWO, 1XKN, 1ZBR, 2CMU, 3H7C 
and 1VKP). Finally, ADI structures have been reported from Streptococcus pyogenes (Sp; PDB 4BOF30), 
Pseudomonas aeruginosa (Pa; PDB 1RXX31), and Mycoplasma arginini (Ma; PDB 1S9R32). Among all 
these, closest structural similarity of PPAD is found with AgDIs (Z-score of 35 according to program 
DALI33; see Fig. 5c), followed by PADs (Z = 18–21; Fig. 5a,b) and ADIs (Z = 18–19).
Superposition of the PPAD α /β -propeller on that of human PAD4 (Fig. 5a,b), EfAgDI (Fig. 5c), and 
PaADI, SpADI and MaADI (data not shown) reveals good overall conservation of the five-blade archi-
tectures, although several decorations in the distinct blades of each family account for large differences, 
especially in the loops surrounding the active-site cleft. In particular, PADs evince a large partially hel-
ical insertion between β 14 and α 6 of PPAD blade IV and lack α 2 of blade I (Fig.  5a). ADIs, in turn, 
evince a large helical sub-domain replacing α 2 and β 4 of PPAD blade I. In common, all propellers are 
closed by the blade V-blade I Velcro mechanism (see above and25) and the catalytic cysteines and histi-
dines are conserved, as well as the two aspartates anchoring the guanidine group to the bottom of the 
active site. In addition, PPAD shares with ADIs and PADs the two arginines binding the main chain of 
the substrate. While these firmly bind the substrate C-terminus in PPAD and ADIs, in PADs they are 
slightly reoriented and only bind what would be one of the two carboxylate oxygens in addition to the 
upstream peptide carbonyl (Fig. 5b). This, together with the replacement of PPAD Y233 of the Michaelis 
loop by serine (S468; PAD4; residue numbering of proteins distinct from PPAD in italics) or threonine 
(T468; PAD2), provides enough space in PADs to allow for a C-terminal extension of the substrate. 
Furthermore, calcium-dependence of PADs is characterized by several calcium-binding sites8,28, two of 
which occur within the propeller domain: one close to the active site with evident implications for func-
tion and the other at the domain periphery (Fig. 5a). Interestingly, the latter coincides with the sodium 
site of PPAD, so a predominantly structural role for both is suggested. In contrast to PADs and PPAD, 
AgDIs and ADIs, which only process standalone residues, possess completely closed active sites (Fig. 5c).
Most notably, superposition also revealed that all these families possess an equivalent of PPAD aspar-
agine N297, i.e. with a potential role in catalysis (PAD2, N590; PAD4, N588; EfAgDI, N306; HpAgDI, N274; 
PaADI, N360; MaADI, N352; and SpADI, N355). To our knowledge, this was previously unnoticed since this 
residue, which is strictly conserved across citrullinating GMEs, was merely recognized as an important 
residue for proper active-site conformation conserved in the consensus helix of blade V of all families 
(see Fig.  4 in25). In PADs, this asparagine is also conserved in distant orthologs from zebrafish and 
chicken within a shared motif (M/L-V-N-M34), which complements the consensus motif encompassing 
the catalytic cysteine residue (G-E-I/V-H-C-G-T/S). The only notable exception is human PAD6, which 
lacks both motifs and the calcium sites that are essential for activity in the other paralogs and orthologs34. 
This absence, together with the lack of direct evidence for activity in vitro with the assays routinely 
employed for the other PADs, poses the question as to whether PAD6 is an active peptidylarginine 
deiminase or whether it may require further factors or interacting partners for activity35. In any case, it 
is likely to follow a different catalytic mechanism.
In all the above structures, the asparagine is at suitable distances and in appropriate orientations to 
polarize the catalytic cysteine, as found in papain-like cysteine peptidases—in particular, Kgp and RgpB 
have N510—so we suggest that citrullinating GMEs all have a cysteine-histidine-asparagine catalytic triad 
as shown for PPAD (see above). However, in contrast to cysteine peptidases, the three residues do not 
establish a charge-relay system for proton transfer, but rather cysteine-asparagine and histidine act sep-
arately on opposite faces of the plane of the guanidinium (Fig. 4a,b).
Concluding remarks. Structural considerations identified PPAD as a closer relative of AgDIs, which 
are found across bacteria, than of PADs, which are found only in vertebrates. This, in turn, enables us 
to hypothesize that PPAD was acquired through horizontal gene transfer of a bacterial single-domain 
agmatine-citrullinating enzyme. The latter would then have evolved in a different bacterial environment 
under fusion to two new C-terminal domains like those found in cognate RgpB, to be secreted through 
a distinct system. This evolution further yielded a unique function among citrullinating enzymes: deimi-
nation of peptides with a C-terminal arginine. This activity, which complements that of R-type gingipain 
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Figure 5. Structural similarities. (A) Superposed ribbon-plots in stereo of PPAD in its substrate-mimic 
complex (cyan) and human PAD4 (coral; PDB 4DKT54) as found in its covalent thiouronium reaction 
intermediate mimic complex. The side chains of the respective catalytic triads (labeled for PPAD only), 
as well as the two calcium ions of PAD4 (red spheres) and the sodium ion of PPAD (blue sphere) are 
shown, as is the methionine-arginine dipeptide from the PPAD substrate complex (carbons in tan). Most 
loops connecting the blades and the consensus secondary elements within each blade differ in length and 
conformation. (B) Close-up of (A). The side chains of the catalytic triad (not labeled) and Y233 (labeled in 
black) of PPAD are depicted (carbons in cyan), as are several representative residues from human PAD4 
(carbons in coral; labeled in blue italics) and the covalently bound intermediate (carbons in goldenrod). The 
mechanistically-relevant equivalent positions (see Fig. 4a,b) in PPAD/human PAD4 (in italics) are C351/C645, 
H236/H471, N297/N588, D238/D473, D130/D350, W217/W347, Y233/S468, R152/R372, and R154/R374. A red ellipse highlights 
the clash an endodeiminase substrate would have with PPAD Y233. The latter is equivalent to S468 in human 
PAD4, which allows for free space for C-terminally elongated substrates. (C) Same as (A) showing PPAD 
(cyan) and AgDI from Enterococcus faecalis (purple; PDB 2JER26) as found in a covalent adduct with an 
agmatine-derived amidine reaction intermediate. The respective catalytic triads are depicted and that of 
PPAD is also labeled. AgDI main-chain segments diverging from PPAD and mainly accounting for a closed 
active site are pinpointed (① to ⑤). The mechanistically-relevant equivalent positions (see Fig. 4a,b) in 
PPAD/AgDI (in italics) are C351/C357, H236/H218, N297/N306, D238/D220, D130/D96, and W217/W93.
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virulence factors (gingipain-null mutants are devoid of endogenous citrullination), has been demon-
strated for several substrates.
Pathogenic bacteria have evolved sophisticated mechanisms in response to the changing environ-
ment and host antimicrobial defense systems. Post-translational modifications are hailed as one of the 
main factors of pathogens to breach immune tolerance. Among these modifications, citrullination of 
endogenous proteins seems to be a key process in the initiation of autoimmune reactions. To date, P. 
gingivalis is the only prokaryote that is able to citrullinate proteins and peptides. It has been proposed as 
a mechanistic link between PD and RA through its potential capacity of generating citrullinated epitopes 
distinct from endogenous PADs, thus contributing to aggravation of RA. This activity is induced by the 
sole bacterial peptidylarginine deiminase reported to date, PPAD, which also has a role in the interaction 
with host cells, so it may be considered as a double target for PD and RA. In contrast, other abundant 
odontopathogens responsible for PD such as Prevotella intermedia and Fusobacterium nucleatum, which 
both lack a PPAD ortholog, do not evince a link with RA.
Methods
Protein production, purification, and characterization. P. gingivalis PPAD (UniProt database 
[UP] access code Q9RQJ2 or GenBank entry WP_005873463.1 for NCBI gene tag PG_1424) was obtained 
through small-scale homologous overexpression as a secreted protein from plasmid-transformed P. gin-
givalis W83 PPAD-deletion mutant strain Δppad. Briefly, plasmid pT-COW, which confers resistance 
against tetracycline36, was used as expression vector, and plasmid derivatives encoding the wild type (wt) 
and a total of 18 PPAD point mutants (W127A, D130A, D130N, R152A, R154A, R154E, T180A, G182A, H236A, 
H236N, D238A, D238N, C239A, C239E, C239S, N297A, C351S, and C351A; see Table 1) were generated. For this, 
the wt gene sequence plus 1081 upstream base pairs and 267 downstream base pairs was amplified from 
P. gingivalis W83 genomic DNA with primers pTCowPPADf and pTCowPPADr (see Table  1), which 
contained recognition sequences for restriction endonucleases NheI and SphI, respectively. The PCR 
fragment obtained was ligated into pT-COW, previously digested with NheI and SphI, to yield plas-
mid pTPP. Point mutations were thereafter introduced into pTPP by the SLIM method37 using primers 
listed under Table 1 and confirmed by DNA sequencing. Plasmid pTPP or its PPAD-mutating variants 
were introduced into P. gingivalis W83 Δppad by conjugation, and bacteria were grown under anaer-
obic conditions (85% N2, 5% H2 and 10% CO2) in liquid Schaedler broth supplemented with hemin 
(5 mg/ml), menadione (0.5 mg/ml), L-cysteine (50 mg/ml), 1 μ g/ml tetracycline, and in the presence or 
absence of 4,4’-dithiodipyridine (DTDP). Expression levels were monitored by Western-blot analysis. 
For this, 30 μ l of P. gingivalis liquid cultures at OD600 = 1.0 were separated on SDS-PAGE and transferred 
to PVDF membranes. Primary PPAD antibodies (kindly provided by Patrick Venables, Oxford) were 
used in 1:1,000 dilution, secondary HRP-conjugated goat anti-rabbit (Amersham) antibodies were used 
at 1:10,000 dilution. Cell cultures obtained in the absence of DTDP were used for functional tests (see 
below). In addition, preparations at a somewhat larger scale—limited by the intrinsic difficulties of culti-
vating P. gingivalis—for structural studies were performed for wt PPAD (DTDP–treated and –untreated) 
and DTDP-untreated PPAD mutant C351A (PPAD–C351A) and purified according to20.
Protein identity and purity were assessed by 15% Tricine-SDS-PAGE stained with Coomassie blue, 
peptide-mass fingerprinting of tryptic protein digests (PMF), N-terminal sequencing through Edman 
degradation, and mass spectrometry (MS). Ultrafiltration steps were performed with Vivaspin 15 and 
Vivaspin 500 filter devices of 10 kDa cut-off (Sartorius Stedim Biotech). Protein concentrations were esti-
mated applying the respective theoretical extinction coefficients by measuring A280 in a spectrophotom-
eter (NanoDrop). Concentrations were also measured by the BCA Protein Assay Kit (Thermo Scientific) 
with bovine serum albumin as a standard.
Activity assays. PPAD endo- and exodeimininase activities were determined against kininogen-derived 
peptides of sequence G-F-S-P-F-R-S-S and P-P-G-F-S-P-F-R, respectively. Briefly, peptides (30 μ g) were 
incubated for 2 h at 37 °C in 100 mM Tris-HCl, pH 7.5 supplemented with 10 mM L-cysteine in the 
presence of P. gingivalis PPAD (0.12, 1.2, 12 and 120 mU) in 30 μ l-reaction volumes (final peptide con-
centration 1 mg/ml). Respective controls were prepared with the same amount of peptide incubated in 
the reaction buffer alone. Reactions were stopped by addition of 80 μ l 0.5% trifluoroacetic acid (TFA) in 
HPLC-quality water and the samples were further analyzed by HPLC using an ÄKTA Micro chromatog-
raphy system (GE Healthcare) coupled with an Aeris Peptide XB-C18 4.6/150 column (Phenomenex). 
Peptides were resolved in 19 column volumes using a 2–80% gradient of phase A (0.1% TFA) and phase 
B (80% acetonitrile, 0.08% TFA) at 1.5 ml/min flow rate. Eluted peaks were fractionated and citrul-
lination was assessed by MS using a HCT Ultra ETD II ESI Iontrap mass spectrometer (Bruker). To 
determine the velocity of deimination, peptides were incubated with 0.12 mU (1 h) and 120 mU (2 h) 
PPAD, respectively, in triplicates. Peak integration data were used to determine the amount of modified 
peptide in each peak (~11% and ~4.5% for P-P-G-F-S-P-F-Cit and G-F-S-P-F-Cit-S-S, respectively) and 
estimate the reaction velocity (in pmol·mU−1·h−1± SD). We found that when P-P-G-F-S-P-F-R became 
completely citrullinated after overnight incubation (0.12–12 mU), G-F-S-P-F-R-S-S was not modified. 
Only at ten-fold higher PPAD concentration (120 mU) was certain time-dependent citrillunation of the 
endosubstrate observed, with 5% of peptide being modified after 2 h. Comparatively, 11% of the exosub-
strate was citrullinated after 1 h at a thousand-fold lower PPAD concentration (0.12 mU; see Fig. 3a,b).
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Competence of wt and mutant PPADs was assessed by the amount of citrulline produced accord-
ing to a sensitive colorimetric assay38. Results obtained from tree independent assays were adjusted to 
OD600 = 1.0 and presented as % of the activity of pTPP-transformed Δppad producing wt PPAD.
Crystallization and diffraction data collection. Prior to crystallization, DTDP–treated and –
untreated wt PPAD and DTDP–untreated PPAD–C351A were dialyzed overnight against buffer A (20 mM 
Tris-HCl, 20 mM sodium chloride, pH 7.5) and further purified by ionic-exchange chromatography on a 
TSKgel DEAE-2SW column (TOSOH Bioscience) equilibrated with buffer A. A gradient of 4–60% buffer 
B (20 mM Tris-HCl, 500 mM sodium chloride, pH 7.5) was applied over 30 ml and samples were col-
lected and pooled. Finally, each pool was concentrated by ultrafiltration and subjected to size-exclusion 
chromatography on a Superdex 75, 10/300 column (GE Healthcare Life Sciences) equilibrated with buffer 
C (20 mM Tris-HCl, 150 mM sodium chloride, pH 7.5).
Crystallization assays were performed by the sitting-drop vapor diffusion method. Reservoir solu-
tions were prepared by a Tecan robot and 100 nL crystallization drops were dispensed on 96 × 2-well 
MRC plates (Innovadyne) by a Phoenix nanodrop robot (Art Robbins) or a Cartesian Microsys 4000 
XL (Genomic Solutions) robot at the joint IBMB/IRB Automated Crystallography Platform at Barcelona 
Science Park. Plates were stored in Bruker steady-temperature crystal farms at 4 °C and 20 °C. Successful 
conditions were scaled up to the microliter range in 24-well Cryschem crystallization dishes (Hampton 
Research).
The best crystals of wt PPAD with 4-thiopyridine but without substrate (PPAD–TP; substrate free) 
resulting from DTDP treatment during production (see above) were obtained at 20 °C from 1 μ l:1 μ l 
drops with protein solution at 20–25 mg/ml concentration in 20 mM Tris-HCl pH 7.4, 100 mM sodium 
chloride and 100 mM sodium acetate (pH 4.5), 25% [w/v] polyethylene glycol 3,350 as reservoir solu-
tion. PPAD mutant C351A in complex with the dipeptide methionine-arginine (PPAD–C351A+ M-R; sub-
strate complex) was crystallized similarly but with 100 mM tri-sodium citrate, 20% [w/v] polyethylene 
glycol 3,000, pH 5.5–6.5 as reservoir solution instead. Finally, wt DTDP-untreated PPAD in complex 
with the dipeptide aspartate-glutamine (PPAD+ D-Q; substrate-mimic complex) was crystallized with 
100 mM tri-sodium citrate, 2 M ammonium sulfate, pH 5.5–6.5 as reservoir solution. All crystals con-
tained protein spanning A44-A475 as determined by Edman degradation and MS analysis. Crystals were 
cryo-protected by rapid passage through drops containing increasing concentrations of glycerol (up to 
15% [v/v]). Complete diffraction datasets were collected at 100 K from liquid-N2 flash cryo-cooled crys-
tals (Oxford Cryosystems 700 series cryostream) on a Pilatus 6 M pixel detector (from Dectris) at beam 
line XALOC of ALBA synchrotron (Barcelona, Spain39). Further data were collected on the same detector 
type at beam line ID23-1 of ESRF synchrotron (Grenoble, France) within the Block Allocation Group 
“BAG Barcelona.” Diffraction data were integrated, scaled, merged, and reduced with program XDS40. 
PPAD–TP, PPAD–C351A+ M-R, and PPAD+ D-Q crystals all contained one protein molecule per asym-
metric unit (solvent content, respectively, 41%, 44% and 48%), had the symmetry of the space groups 
P212121, C2, and P212121, respectively, and had different cell constants (see Table  2 for data processing 
statistics).
Structure solution and refinement. A similarity search with programs PSI-BLAST and HHPRED 
identified only low homology models (PDB 3HVM, 1ZBR, 1XKN, 2JER, 3H7C, and 2EWO), which 
failed to render a solution by conventional molecular replacement and Patterson-search methods. At this 
point, wt PPAD–TP crystal diffraction data were used for structure solution with ARCIMBOLDO41–43. 
Therefore, 16 datasets with resolutions ranging from 3.0 Å to 1.5 Å from different native protein crystals or 
heavy-ion soaks with similar cell dimensions were merged with program XPREP. A collection of structure 
fragments was generated from the six aforementioned distant structural relatives, and ARCIMBOLDO 
runs were set up in parallel with these fragments and libraries41,42. These calculations eventually enabled 
structure solution (see44,45 for details), and the resulting phase set was subjected to density modification 
and autotracing with SHELXE46, which yielded an improved set of phases and a partial model. These 
phases and the resulting Fourier map enabled subsequent manual model building with the COOT pro-
gram47, which alternated with crystallographic refinement with PHENIX48 and BUSTER/TNT49 under 
inclusion of TLS refinement, until the final refined model of PPAD–TP was obtained. This consisted of 
residues A44-N464, one structural sodium ion, seven glycerols, 460 solvent molecules, and 4-thiopyridine 
moieties respectively attached to the Sγ atoms of C351, C462, and C239. The final Fourier map indicated that 
the side chain of the latter residue was present in two alternate conformations, one bound to thiopyridine 
and the other with the sulfur as sulfoxide. See Table 2 for final refinement and model quality statistics.
The structure of PPAD–C351A+ M-R was solved with PHASER within the PHENIX50 package using 
the refined coordinates of PPAD–TP. The adequately rotated and translated molecule yielded accurate 
phases, which enabled calculation of an initial Fourier map. Subsequent model completion and refine-
ment proceeded as above. The final model of PPAD–C351A+ M-R contained residues A44-M463, one struc-
tural sodium cation, a dipeptide of tentative sequence methionine-arginine, five glycerols, one chloride, 
two azides, 426 solvent molecules, and a free cysteine disulfide-bonded to C462. See Table  2 for final 
refinement and model quality statistics.
The structure of PPAD+ D-Q was solved similarly. Model completion and refinement proceeded as 
above. The final model comprised residues A44-E465, one sodium cation, a dipeptide of tentative sequence 
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aspartate-glutamine (the distinction between aspartate/asparagine and glutamate/glutamine was per-
formed based on surrounding interacting partners), three glycerols, five phosphates, one chloride, one 
azide, and 689 solvent molecules. See Table 2 for final refinement and model quality statistics.
Miscellaneous. Ideal coordinates and parameters for crystallographic refinement of non-standard 
ligands were obtained from the PRODRG server51. Structural similarity searches were performed with 
DALI33, and structure figures were prepared with programs COOT and CHIMERA52. Experimental 
structures were validated with MOLPROBITY53. The final coordinates of P. gingivalis PPAD–TP (sub-
strate free), PPAD–C351A+ M-R (substrate complex), and PPAD+ D-Q (substrate-mimic complex) are 
deposited with the PDB at www.pdb.org (access codes 4YT9, 4YTG, and 4YTB).
References
1. Krebs, H. A. & Henseleit, K. Untersuchungen über die Harnstoffbildung im Tierkörper. Hoppe-Seylers Z. Physiol. Chem. 210, 
33–66 (1932).
2. Woo, H. I., Park, H. D. & Lee, Y. W. Molecular genetics of citrullinemia types I and II. Clin. Chim. Acta 431, 1–8 (2014).
3. El-Hattab, A. W., Emrick, L. T., Chanprasert, S., Craigen, W. J. & Scaglia, F. Mitochondria: role of citrulline and arginine 
supplementation in MELAS syndrome. Int. J. Biochem. Cell Biol. 48, 85–91 (2014).
4. György, B., Toth, E., Tarcsa, E., Falus, A. & Buzas, E. I. Citrullination: a posttranslational modification in health and disease. Int. 
J. Biochem. Cell Biol. 38, 1662–1677 (2006).
5. Baka, Z. et al. Citrullination under physiological and pathological conditions. Joint Bone Spine 79, 431–436 (2012).
6. Muller, S. & Radic, M. Citrullinated autoantigens: from diagnostic markers to pathogenetic mechanisms. Clin. Rev. Allergy 
Immunol. 48, in press (2015).
7. Nijenhuis, S., Zendman, A. J. W., Vossenaar, E. R., Pruijn, G. J. M. & van Venrooij, W. J. Autoantibodies to citrullinated proteins 
in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin. Chim. Acta 350, 17–34 
(2004).
8. Slade, D. J. et al. Protein arginine deiminase 2 binds calcium in an ordered fashion: implications for inhibitor design. ACS Chem. 
Biol. 10, 1043–1053 (2015).
9. Gudmann, N. S., Hansen, N. U., Jensen, A. C., Karsdal, M. A. & Siebuhr, A. S. Biological relevance of citrullinations: diagnostic, 
prognostic and therapeutic options. Autoimmunity 48, 73–79 (2014).
10. Mallya, R. K. et al. Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. 
Clin. Exp. Immunol. 51, 17–20 (1983).
11. MacGregor, A. J. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. 
Arthritis Rheum. 43, 30–37 (2000).
12. Seymour, G. J., Ford, P. J., Cullinan, M. P., Leishman, S. & Yamazaki, K. Relationship between periodontal infections and systemic 
disease. Clin. Microbiol. Infect. 13 Suppl 4, 3–10 (2007).
13. Preshaw, P. M. et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 55, 21–31 (2012).
14. de Pablo, P., Chapple, I. L., Buckley, C. D. & Dietrich, T. Periodontitis in systemic rheumatic diseases. Nat. Rev. Rheumatol. 5, 
218–224 (2009).
15. Maresz, K. J. et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its 
unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 9, e1003627 (2013).
16. Mayo, C. H. Focal infection of dental origin. Dent. Cosmos 64, 1206–1208 (1922).
17. Potempa, J., Sroka, A., Imamura, T. & Travis, J. Gingipains, the major cysteine proteinases and virulence factors of Porphyromonas 
gingivalis: structure, function and assembly of multidomain protein complexes. Curr. Prot. Pept. Sci. 4, 397–407 (2003).
18. McGraw, W. T., Potempa, J., Farley, D. & Travis, J. Purification, characterization, and sequence analysis of a potential virulence 
factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect. Immun. 67, 3248–3256 (1999).
19. Casiano-Colon, A. & Marquis, R. E. Role of the arginine deiminase system in protecting oral bacteria and an enzymatic basis 
for acid tolerance. Appl. Environ. Microbiol. 54, 1318–1324 (1988).
20. Bielecka, E. et al. Peptidyl arginine deiminase from Porphyromonas gingivalis abolishes anaphylatoxin C5a activity. J. Biol. Chem. 
289, 32481–32487 (2014).
21. Sato, K. et al. Identification of Porphyromonas gingivalis proteins secreted by the Por secretion system. FEMS Microbiol. Lett. 338, 
68–76 (2013).
22. de Diego, I. et al. Structure and mechanism of cysteine peptidase gingipain K (Kgp), a major virulence factor of Porphyromonas 
gingivalis in periodontitis. J. Biol. Chem. 289, 32291–32302 (2014).
23. de Diego, I. et al. Porphyromonas gingivalis virulence factor gingipain RgpB shows a unique zymogenic mechanism for cysteine 
peptidases. J. Biol. Chem. 288, 14287–14296 (2013).
24. Eichinger, A. et al. Crystal structure of gingipain R: an Arg-specific bacterial cysteine proteinase with a caspase-like fold. EMBO 
J. 18, 5453–5462 (1999).
25. Shirai, H., Mokrab, Y. & Mizuguchi, K. The guanidino-group modifying enzymes: structural basis for their diversity and 
commonality. Proteins 64, 1010–1023 (2006).
26. Llácer, J. L. et al. The gene cluster for agmatine catabolism of Enterococcus faecalis: study of recombinant putrescine transcarbamylase 
and agmatine deiminase and a snapshot of agmatine deiminase catalyzing its reaction. J. Bacteriol. 189, 1254–1265 (2007).
27. Curran, T. M., Lieou, J. & Marquis, R. E. Arginine deiminase system and acid adaptation of oral streptococci. Appl. Environ. 
Microbiol. 61, 4494–4496 (1995).
28. Arita, K. et al. Structural basis for Ca2+-induced activation of human PAD4. Nat. Struct. Mol. Biol. 11, 777–783 (2004).
29. Jones, J. E. et al. Characterization and inactivation of an agmatine deiminase from Helicobacter pylori. Bioorg. Chem. 38, 62–73 
(2010).
30. Henningham, A. et al. Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus. 
MBio 4, e00509–e00513 (2013).
31. Galkin, A. et al. Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target. J. 
Biol. Chem. 279, 14001–14008 (2004).
32. Das, K. et al. Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism. 
Structure 12, 657–667 (2004).
33. Holm, L. & Rosenström, P. Dali server: conservation mapping in 3D. Nucleic Acids Res. 38, W545–W549 (2010).
34. Vossenaar, E. R., Zendman, A. J., van Venrooij, W. J. & Pruijn, G. J. PAD, a growing family of citrullinating enzymes: genes, 
features and involvement in disease. Bioessays 25, 1106–1118 (2003).
www.nature.com/scientificreports/
1 6Scientific RepoRts | 5:11969 | DOi: 10.1038/srep11969
35. Rose, R., Rose, M. & Ottmann, C. Identification and structural characterization of two 14-3-3 binding sites in the human 
peptidylarginine deiminase type VI. J. Struct. Biol. 180, 65–72 (2012).
36. Bélanger, M., Rodrigues, P. & Progulske-Fox, A. Genetic manipulation of Porphyromonas gingivalis. Curr. Protoc. Microbiol. 
Chapter 13, Unit13C 12 (2007).
37. Chiu, J., March, P. E., Lee, R. & Tillett, D. Site-directed, ligase-independent mutagenesis (SLIM): a single-tube methodology 
approaching 100% efficiency in 4h. Nucleic Acids Res. 32, e174 (2004).
38. Boyde, T. R. & Rahmatullah, M. Optimization of conditions for the colorimetric determination of citrulline, using diacetyl 
monoxime. Anal. Biochem. 107, 424–431 (1980).
39. Juanhuix, J. et al. Developments in optics and performance at BL13-XALOC, the macromolecular crystallography beamline at 
the ALBA synchrotron. J. Synchrotron Radiat. 21, 679–689 (2014).
40. Kabsch, W. XDS. Acta Crystallogr. sect. D 66, 125–132 (2010).
41. Rodriguez, D. D. et al. Crystallographic ab initio protein structure solution below atomic resolution. Nat. Methods 6, 651–653 
(2009).
42. Sammito, M. et al. Exploiting tertiary structure through local folds for crystallographic phasing. Nat. Methods 10, 1099–1101 
(2013).
43. Millán, C. et al. Combining phase information in reciprocal space for ARCIMBOLDO. Acta Crystallogr. sect. D 71, in press 
(2015).
44. Sammito, M. et al. Structure solution with ARCIMBOLDO using fragments derived from distant homology models. FEBS J. 281, 
4029–4045 (2014).
45. Millán, C., Sammito, M. & Usón, I. Macromolecular ab initio phasing enforcing secondary and tertiary structure. IUCrJ 2, 95–
105 (2015).
46. Thorn, A. & Sheldrick, G. M. Extending molecular-replacement solutions with SHELXE. Acta Crystallogr. sect. D 69, 2251–2256 
(2013).
47. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. sect. D 66, 486–501 
(2010).
48. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. sect. D 68, 
352–367 (2012).
49. Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta 
Crystallogr. sect. D 68, 368–380 (2012).
50. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658–674 (2007).
51. Schüttelkopf, A. W. & van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta 
Crystallogr. sect. D 60, 1355–1363 (2004).
52. Pettersen, E. F. et al. UCSF Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 
1605–1612 (2004).
53. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. sect. D 66, 
12–21 (2010).
54. Jones, J. E. et al. Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem. 
Biol. 7, 160–165 (2012).
55. García-Castellanos, R. et al. Three-dimensional structure of MecI: Molecular basis for transcriptional regulation of staphylococcal 
methicillin resistance. J. Biol. Chem. 278, 39897–39905 (2003).
56. Weiss, M. S. Global indicators of X-ray quality. J. Appl. Cryst. 34, 130–135 (2001).
57. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030–1033 (2012).
58. Engh, R. & Huber, R. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr. sect. A 47, 
392–400 (1991).
59. Davis, I. W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, 
W375–W383 (2007).
Acknowledgments
We are grateful to Joan Pous and Xandra Kreplin from the joint IBMB/IRB Automated Crystallography 
Platform for assistance during crystallization experiments and to Robin Rycroft for very helpful 
contributions to the manuscript. We further acknowledge the help provided by local contacts at the 
ESRF and ALBA synchrotrons. We are also grateful to Adam Lesner from the University of Gdansk 
and Oliwia Bochenska from the Małopolska Center of Biotechnology for peptide synthesis and mass 
spectrometry analysis. This study was financially supported in part by grants from European, US 
American, Polish, Spanish, and Catalan agencies (UMO-2012/04/A/NZ1/00051, UMO-2012/05/B/
NZ6/00581, UMO-2013/08/W/NZ1/00696, 2137/7.PR-EU/2011/2, 2975/7.PR/13/2014/2, NIH NIDCR 
DE09761; FP7-PEOPLE-2011-ITN-290246 “RAPID”; FP7-HEALTH-2012-306029-2 “TRIGGER”; FP7-
HEALTH-2010-261460 “Gums&Joints”; BFU2012-32862; BFU2012-33516; BFU2012-35367; BIO2013-
49320-EXP; MDM-2014-0435; 2014SGR9 and 2014SGR997). IGF acknowledges an FPU-fellowship 
(AP2010-3799) from the former Spanish Ministry for Education, Culture and Sport. TG acknowledges 
a “Juan de la Cierva” research contract (JCI-2012-13573) from the Spanish Ministry for Economy and 
Competitiveness. The Department of Structural Biology of IBMB is a “María de Maeztu” Unit of Excellence 
from the Ministry of Economy and Competitiveness. Funding for data collection was provided in part 
by ESRF. The Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University at 
Kraków (Poland) is a partner of the Leading National Research Center (KNOW) supported by the Polish 
Ministry of Science and Higher Education.
Author Contributions
F.X.G.-R., M.S. and J.P. designed the research. T.G., D.M., T.K., I.G.-F., T.G., B.S., A.S., C.M., I.U., F.V., 
B.P., P.M., M.S. and F.X.G.-R. performed the experiments and/or data analysis. F.X.G.-R., M.S. and J.P. 
wrote the paper with input from all authors.
www.nature.com/scientificreports/
17Scientific RepoRts | 5:11969 | DOi: 10.1038/srep11969
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Goulas, T. et al. Structure and mechanism of a bacterial host-protein 
citrullinating virulence factor, Porphyromonas gingivalis peptidylarginine deiminase. Sci. Rep. 5, 11969; 
doi: 10.1038/srep11969 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
